Is This LLY Stock Dip Big Enough To Be Worth Buying?

Eli Lilly (LLY) trades near $1,120, about 13% below the high it set in August, and the question is whether to step in. The stock's record after sharp falls is clean but short. That record asks for the better part of a year and more pain before it pays. And this fall is not the kind of fall that record is built on.

What Has Buying An Eli Lilly Fall Actually Paid?

While our lookback runs back to 2010, Eli Lilly only triggered a 20% fall inside 30 trading days on three occasions—all clustered within a nine-month span between November 2024 and August 2025. Because these events overlap during a single extended pullback, their subsequent 48% median gain reflects one continuous recovery cycle rather than three separate historical tests. Also, three events is a thin base, and a median is not a promise.

That record cost something to collect. Buyers endured a median worst further decline of 13% after the dip, and the median time from a dip to the peak of the recovery was about 333 days, close to eleven months. What this record rewards is patience, not timing.

LLY had 3 events since 1/1/2010 where the dip threshold of -20% within 30 days was triggered

55% median peak return following a dip event

333 days is the median time to peak return after a dip event

13% median max drawdown within 1 year of dip event

Patience only pays if the company keeps growing into the price. Eli Lilly grew revenue 49.6% over the trailing twelve months, to $79.67 billion, and turned 35.3% of that into operating cash flow. Mounjaro and Zepbound added $6.3 billion of revenue year over year in the second quarter of 2026. Nothing in that looks like a business in trouble.

The complication is price. Reported U.S. price fell 3% in the second quarter of 2026, and management said that excluding a change to estimates for rebates and discounts, it fell 9%. Volume carries the growth now , and it is coming cheaper. The Medicare GLP-1 Bridge program launched on July 1 and hands 20 million eligible Americans coverage for obesity medicines at an out-of-pocket $50 a month.

Two things support stepping in. Growth is still strong, and retatrutide, a new obesity medicine, is headed for a U.S. submission in the first quarter of 2027.